136 related articles for article (PubMed ID: 26137584)
1. Unraveling the Activation Mechanism of Taspase1 which Controls the Oncogenic AF4-MLL Fusion Protein.
Sabiani S; Geppert T; Engelbrecht C; Kowarz E; Schneider G; Marschalek R
EBioMedicine; 2015 May; 2(5):386-95. PubMed ID: 26137584
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the catalytically impaired Taspase1 T234V or Taspase1 D233A variants does not have a dominant negative effect in T(4;11) leukemia cells.
Bier C; Hecht R; Kunst L; Scheiding S; Wünsch D; Goesswein D; Schneider G; Krämer OH; Knauer SK; Stauber RH
PLoS One; 2012; 7(5):e34142. PubMed ID: 22570686
[TBL] [Abstract][Full Text] [Related]
3. The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
Pless B; Oehm C; Knauer S; Stauber RH; Dingermann T; Marschalek R
Leukemia; 2011 Apr; 25(4):663-70. PubMed ID: 21233834
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Salvatore F; Esposito G
Cell Oncol (Dordr); 2019 Dec; 42(6):829-845. PubMed ID: 31493143
[TBL] [Abstract][Full Text] [Related]
5. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia.
Zhao Z; Wang L; Volk AG; Birch NW; Stoltz KL; Bartom ET; Marshall SA; Rendleman EJ; Nestler CM; Shilati J; Schiltz GE; Crispino JD; Shilatifard A
Genes Dev; 2019 Jan; 33(1-2):61-74. PubMed ID: 30573454
[TBL] [Abstract][Full Text] [Related]
6. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins.
Ng MH; Ng RK; Kong CT; Jin DY; Chan LC
Exp Hematol; 2010 Jun; 38(6):481-8. PubMed ID: 20362031
[TBL] [Abstract][Full Text] [Related]
7. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.
Dong Y; Van Tine BA; Oyama T; Wang PI; Cheng EH; Hsieh JJ
Cell Res; 2014 Nov; 24(11):1354-66. PubMed ID: 25267403
[TBL] [Abstract][Full Text] [Related]
8. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
Ahmad K; Scholz B; Capelo R; Schweighöfer I; Kahnt AS; Marschalek R; Steinhilber D
Oncotarget; 2015 Sep; 6(28):25784-800. PubMed ID: 26329759
[TBL] [Abstract][Full Text] [Related]
9. circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression.
Huang W; Fang K; Chen TQ; Zeng ZC; Sun YM; Han C; Sun LY; Chen ZH; Yang QQ; Pan Q; Luo XQ; Wang WT; Chen YQ
J Hematol Oncol; 2019 Oct; 12(1):103. PubMed ID: 31623653
[TBL] [Abstract][Full Text] [Related]
10. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
[TBL] [Abstract][Full Text] [Related]
11. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.
Takeda S; Chen DY; Westergard TD; Fisher JK; Rubens JA; Sasagawa S; Kan JT; Korsmeyer SJ; Cheng EH; Hsieh JJ
Genes Dev; 2006 Sep; 20(17):2397-409. PubMed ID: 16951254
[TBL] [Abstract][Full Text] [Related]
12. The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.
Lin S; Luo RT; Shrestha M; Thirman MJ; Mulloy JC
Blood; 2017 Aug; 130(7):903-907. PubMed ID: 28637661
[TBL] [Abstract][Full Text] [Related]
13. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.
Xia ZB; Popovic R; Chen J; Theisler C; Stuart T; Santillan DA; Erfurth F; Diaz MO; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):14028-33. PubMed ID: 16169901
[TBL] [Abstract][Full Text] [Related]
14. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.
Thomas M; Gessner A; Vornlocher HP; Hadwiger P; Greil J; Heidenreich O
Blood; 2005 Nov; 106(10):3559-66. PubMed ID: 16046533
[TBL] [Abstract][Full Text] [Related]
15. Nuclear FGFR2 Interacts with the MLL-AF4 Oncogenic Chimera and Positively Regulates
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Cattaneo F; Ammendola R; Esposito G
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924850
[TBL] [Abstract][Full Text] [Related]
16. Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair.
Castaño J; Herrero AB; Bursen A; González F; Marschalek R; Gutiérrez NC; Menendez P
Oncotarget; 2016 May; 7(21):30440-52. PubMed ID: 27119507
[TBL] [Abstract][Full Text] [Related]
17. FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs.
Bueno C; Ayllón V; Montes R; Navarro-Montero O; Ramos-Mejia V; Real PJ; Romero-Moya D; Araúzo-Bravo MJ; Menendez P
Blood; 2013 May; 121(19):3867-78, S1-3. PubMed ID: 23479570
[TBL] [Abstract][Full Text] [Related]
18. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression.
Hsieh JJ; Cheng EH; Korsmeyer SJ
Cell; 2003 Oct; 115(3):293-303. PubMed ID: 14636557
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding proteins of KHDRBS and IGF2BP families control the oncogenic activity of MLL-AF4.
Okuda H; Miyamoto R; Takahashi S; Kawamura T; Ichikawa J; Harada I; Tamura T; Yokoyama A
Nat Commun; 2022 Nov; 13(1):6688. PubMed ID: 36335100
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of human Taspase1, a crucial protease regulating the function of MLL.
Khan JA; Dunn BM; Tong L
Structure; 2005 Oct; 13(10):1443-52. PubMed ID: 16216576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
